Petros Pharmaceuticals, Inc.
PTPI
$0.0275
-$0.0005-1.79%
OTC PK
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 23.49% | 0.59% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 23.49% | -41.02% | |||
| Operating Income | -23.49% | 16.53% | |||
| Income Before Tax | -70.18% | 87.07% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -70.18% | 87.07% | |||
| Earnings from Discontinued Operations | 804.77% | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 340.39% | 75.63% | |||
| EBIT | -23.49% | 16.53% | |||
| EBITDA | -45.64% | 31.21% | |||
| EPS Basic | 86.23% | 64.87% | |||
| Normalized Basic EPS | 92.38% | 93.38% | |||
| EPS Diluted | 86.23% | 64.87% | |||
| Normalized Diluted EPS | 92.38% | 93.38% | |||
| Average Basic Shares Outstanding | 2,131.24% | 187.36% | |||
| Average Diluted Shares Outstanding | 2,131.24% | 187.36% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||